Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 62

Results For "EMA"

2994 News Found

FDA completes inspection of Indoco’s API manufacturing facility at Patalganga with zero observations
Drug Approval | September 19, 2025

FDA completes inspection of Indoco’s API manufacturing facility at Patalganga with zero observations

The inspection concluded with zero form 483 observations


AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment
Clinical Trials | September 18, 2025

AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment

The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo


Novo Nordisk’s Wegovy delivered 16.6% weight loss
News | September 18, 2025

Novo Nordisk’s Wegovy delivered 16.6% weight loss

Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight


Bayer inaugurates new phytomedicines lab facility
News | September 18, 2025

Bayer inaugurates new phytomedicines lab facility

The lab will facilitate the development of herbal and natural-based solutions


GSK to invest $30 billion in R&D, manufacturing in US over next 5 years
News | September 17, 2025

GSK to invest $30 billion in R&D, manufacturing in US over next 5 years

Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs


HCG Manavata launches awareness campaign for prostate cancer
News | September 17, 2025

HCG Manavata launches awareness campaign for prostate cancer

Encouraging early detection and breaking the silence around men’s health


FDA approves Lupin’s Lenalidomide capsules
Drug Approval | September 17, 2025

FDA approves Lupin’s Lenalidomide capsules

Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma


FDA launches crackdown on deceptive drug advertising
Policy | September 16, 2025

FDA launches crackdown on deceptive drug advertising

The FDA is beginning rulemaking to close the “adequate provision” loophole


CIDSCON 2025 emphasized a multi-faceted approach to tackle AMR
Healthcare | September 16, 2025

CIDSCON 2025 emphasized a multi-faceted approach to tackle AMR

The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness